StockData

Quantum Cyber vs Silence Therapeutics

QUCY and SLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How QUCY and SLN compare

Quantum Cyber grew revenue faster over the last twelve months (−39.9% versus −98.2% for Silence Therapeutics).

Quantum Cyber keeps more of each dollar of sales as profit, with a net margin of −3018% compared with −11277% at Silence Therapeutics.

Silence Therapeutics scores higher on the StockData Score (7 against 3 for Quantum Cyber), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricQUCYSLN
Size and price
Share price$0.630$19.80
Change, 1 year−53.7%186%
Change, 5 years−93.6%−10.0%
Beta (5Y)–0.81
Employees388
StockData Score
Total score37 (better)
Valuation score00
Growth score11
Performance score11
Health score15 (better)
Dividend score00
Growth
Revenue growth (TTM)−39.9% (better)−98.2%
Revenue growth, 5Y average1.7%–
Profitability
Gross margin72.6%95.0% (better)
Operating margin−3005% (better)−12344%
Net margin−3018% (better)−11277%
FCF margin−2045% (better)−9682%
Return on equity−141%−35.6% (better)
Return on invested capital−324%–
Financial health
Debt / equity–0.00
Interest coverage−43.2×–
Current ratio5.5623.94 (better)
Piotroski F-score22
Ownership
Held by institutions2.4%16.6%
Held by insiders–48.1%
Insider net buying, 12 months$0–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.